InterCure (INCR)
(Delayed Data from NSDQ)
$2.48 USD
+0.09 (3.77%)
Updated Jul 12, 2024 03:59 PM ET
After-Market: $2.42 -0.06 (-2.42%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
INCR 2.48 +0.09(3.77%)
Will INCR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for INCR based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for INCR
Asset-Light Expansion Into $8B German Market Adds Potential To This Cannabis Stock On NASDAQ
Intercure Ltd. Files SEC Report, Ensures Transparency
InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference
CRVS, CTMX and NRXP are among premarket gainers
InterCure Reports Strong FY2023: Performance Paves the Way for Global Expansion